Home / Research / Publications / HER2 in endometrioid endometrial adenocarcinoma (E-EMCA): defining incidence, molecular profiles, and outcomes

Publications

HER2 in endometrioid endometrial adenocarcinoma (E-EMCA): defining incidence, molecular profiles, and outcomes

June 2022

– Caris Life Sciences

Key Finding:

5% of endometrioid endometrial adenocarcinomas are HER2+, as assessed by ERBB2 expression, and have a hot immune phenotype.

Learn More

Name(Required)

First Last

Company/Institution(Required)

Role/Title(Required)

Email(Required)